204 filings
6-K
BDRX
Biodexa Pharmaceuticals Plc
19 Apr 24
Preliminary Results for the Year Ended 31 December 2023
8:19am
6-K
BDRX
Biodexa Pharmaceuticals Plc
23 Feb 24
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
1:25pm
6-K
BDRX
Biodexa Pharmaceuticals Plc
22 Jan 24
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
8:51am
6-K
BDRX
Biodexa Pharmaceuticals Plc
29 Dec 23
Biodexa Appoints Ann Merchant to the Board of Directors
12:10pm
6-K
BDRX
Biodexa Pharmaceuticals Plc
21 Dec 23
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
4:30pm
6-K
uvaaen19mi7
6 Dec 23
Current report (foreign)
4:15pm
6-K
ykcweao x8kq
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
wlbtuup
3 Oct 23
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
10:10am
6-K
4gzgk2ru297032 rx48l
29 Sep 23
Current report (foreign)
4:45pm
6-K
oj9j5 5tl
24 Jul 23
Current report (foreign)
8:07am
6-K
8nf23usl
10 Jul 23
Current report (foreign)
8:27am
6-K
th99c09wur 4sydnirg
6 Jul 23
Results of Appeal of Delisting Determination
4:43pm
6-K
ujmpf
6 Jul 23
Current report (foreign)
11:52am
6-K
ulijugjdfie9n24f3
22 Jun 23
Current report (foreign)
4:33pm
6-K
hsroh9 wm8d
20 Jun 23
Current report (foreign)
8:16am
6-K
58mlb
15 Jun 23
Current report (foreign)
4:51pm
6-K
qlbj6c4ai640
14 Jun 23
Results of Annual General Meeting and General Meeting
8:35am
6-K
j0tynou
1 Jun 23
Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLC(formerly Midatech Pharma Plc)Annual Report 2022
7:27am
6-K
uelpa y5cdknud1v36gf
26 May 23
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
4:24pm
6-K/A
p6fw f0bmqjtb
25 May 23
Amendment No. 2
9:53pm